CLAIMS

What is claimed is:

1. A method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof.

2. The method of Claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.

3. The method of Claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.

4. The method of Claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

5. The method of Claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.

6. The method of Claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.

7. The method of Claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.

8. The method of Claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.

9. A method for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof.

10. The method of Claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.

11. The method of Claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.

12. The method of Claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

13. The method of Claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.

14. The method of Claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.

15. The method of Claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.

16. The method of Claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.

17. A pharmaceutical composition for inhibiting HIV protease comprising a pharmaceutical carrier and a therapeutically effective amount of a combination of ritonavir or a pharmaceutically acceptable salt thereof and an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition for inhibiting an HIV infection comprising a pharmaceutical carrier and a therapeutically effective amount of a combination of ritonavir or a pharmaceutically acceptable salt thereof and an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof.

19. A method for inhibiting HIV protease comprising administering to a human in need of such treatment a therapeuctially effective amount of a combination of ritonavir or a pharmaceutically acceptable salt thereof and an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof.

20. A method for inhibiting an HIV infection comprising administering to a human in need of such treatment a therapeuctially effective amount of a combination of ritonavir or a pharmaceutically acceptable salt thereof and an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition for inhibiting HIV protease comprising a pharmaceutical carrier and a therapeutically effective amount of a combination of ritonavir or a pharmaceutically acceptable salt thereof and a compound selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017 or a pharmaceutically acceptable salt thereof.

22. The composition of Claim 21 wherein the compound is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

23. The composition of Claim 21 wherein the compound is saquinavir.

24. The composition of Claim 21 wherein the compound is VX-478.

25. The composition of Claim 21 wherein the compound is MK-639.

26. The composition of Claim 21 wherein the compound is AG1343.

27. A pharmaceutical composition for inhibiting an HIV infection comprising a pharmaceutical carrier and a therapeutically effective amount of a combination of ritonavir or a pharmaceutically acceptable salt thereof and a compound selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017 or a pharmaceutically acceptable salt thereof.

28. The composition of Claim 27 wherein the compound is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

29. The composition of Claim 27 wherein the compound is saquinavir.

30. The composition of Claim 27 wherein the compound is VX-478.

31. The composition of Claim 27 wherein the compound is MK-639.

32. The composition of Claim 27 wherein the compound is AG1343.

33. A method for inhibiting HIV protease comprising administering to a human in need of such treatment a therapeuctially effective amount of a combination of ritonavir or a pharmaceutically acceptable salt thereof and a compound selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017 or a pharmaceutically acceptable salt thereof.

34. The method of Claim 33 wherein the compound is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

35. The method of Claim 33 wherein the compound is saquinavir.

36. The method of Claim 33 wherein the compound is VX-478.

37. The method of Claim 33 wherein the compound is MK-639.

38. The method of Claim 33 wherein the compound is AG1343.

39. A method for inhibiting an HIV infection comprising administering to a human in need of such treatment a therapeuctially effective amount of a combination of ritonavir or a pharmaceutically acceptable salt thereof and a

compound selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017 or a pharmaceutically acceptable salt thereof.

40. The method of Claim 39 wherein the compound is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

41. The method of Claim 39 wherein the compound is saquinavir.

42. The method of Claim 39 wherein the compound is VX-478.

43. The method of Claim 39 wherein the compound is MK-639.

44. The method of Claim 39 wherein the compound is AG1343.